Novel approach may prolong remission after T-cell immunotherapy for leukemia, lymphoma – Healio
|
Novel approach may prolong remission after T-cell immunotherapy for leukemia, lymphoma
Healio Researchers at Seattle Children’s Hospital have launched a first-in-human trial to investigate whether infusions of T-cell antigen–presenting cells prolong the persistence of chimeric antigen receptor T-cell immunotherapy among children with relapsed … |
|
CUA 2017: State of the Art Immunotherapy for Urologic Cancers.
UroToday Since the interferon trials for metastatic kidney cancer in the 1990’s, we have been waiting for subsequent immunotherapy breakthroughs. Over the past several years, we have certainly seen this with the targeting of immune checkpoints, first in … |
UroToday |
CUA 2017: State of the Art Immunotherapy for Urologic Cancers.
UroToday Since the interferon trials for metastatic kidney cancer in the 1990’s, we have been waiting for subsequent immunotherapy breakthroughs. Over the past several years, we have certainly seen this with the targeting of immune checkpoints, first in … Now a cancer drug which avoids pain of chemotherapy?Deccan Chronicle |